EyePoint Pharmaceuticals Inc.

12/06/2023 | Press release | Distributed by Public on 12/06/2023 15:39

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission
FORM 4
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
Cormorant Asset Management, LP
2. Issuer Name and Ticker or Trading Symbol
EyePoint Pharmaceuticals, Inc. [EYPT]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
200 CLARENDON STREET , 52ND FLOOR
3. Date of Earliest Transaction (Month/Day/Year)
(Street)
BOSTON MA 02116
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Join/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code 4. Securities Acquired (A) or Disposed of (D) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct (D) or Indirect (I) 7. Nature of Indirect Beneficial Ownership
Code V Amount (A) or (D) Price
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security 8. Price of Derivative Security 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 11. Nature of Indirect Beneficial Ownership
Code V (A) (D) Date Exercisable Expriation Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Cormorant Asset Management, LP
200 CLARENDON STREET
52ND FLOOR
BOSTON, MA02116



Chen Bihua
C/O CORMORANT ASSET MANAGEMENT, LP
200 CLARENDON STREET, 52ND FLOOR
BOSTON, MA02116



Cormorant Global Healthcare Master Fund, LP
200 CLARENDON STREET
52ND FLOOR
BOSTON, MA02116



Signatures

/s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner 2023-12-06
**Signature of Reporting Person Date
/s/ Bihua Chen 2023-12-06
**Signature of Reporting Person Date
/s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP By: Cormorant Global Healthcare GP, LLC, its General Partner 2023-12-06
**Signature of Reporting Person Date

Explanation of Responses:

(*) If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
(2) Represents the weighted average sale price of Common Stock (the "shares") purchased in a series of open market transactions on the transaction date at prices ranging from $18.30 to $19.30 per share.
(3) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $19.30 to $20.30 per share.
(4) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $20.30 to $21.29 per share.
(5) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $21.30 to $22.29 per share.
(6) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $22.30 to $23.29 per share.
(7) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $23.30 to $24.29 per share.
(8) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $24.30 to $25.29 per share.
(9) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $25.30 to $26.29 per share.
(10) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $26.30 to $27.29 per share.
(11) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $27.30 to $28.29 per share.
(12) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $28.30 to $29.28 per share.
(13) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $29.30 to $30.29 per share.
(14) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $30.30 to $31.29 per share.
(15) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $31.30 to $32.29 per share.
(16) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $32.30 to $33.29 per share.
(17) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $33.30 to $34.29 per share.
(18) Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $34.30 to $34.75 per share.
(19) The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.